The overall ratings of six Medical Devices stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Synergetics USA (NASDAQ:SURG) earns a F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Synergetics USA develops and manufactures medical devices and products for the hospital and healthcare communities. The stock price has fallen 19.8% over the past month, worse than the 5.5% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of SURG stock.
St. Jude Medical‘s (NYSE:STJ) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. St. Jude Medical makes and distributes cardiovascular medical devices. Share prices fell 8.2% over the past month. To get an in-depth look at STJ, get Portfolio Grader’s complete analysis of STJ stock.
CONMED Corp. (NASDAQ:CNMD) is having a tough week. The company’s rating falls from a C to a D rating. Conmed is a medical technology company that emphasizes surgical devices and equipment for minimally invasive procedures and monitoring. The stock also gets an F in Margin Growth. The stock’s trailing PE Ratio is 210.40. For a full analysis of CNMD stock, visit Portfolio Grader.
The rating of Dentsply International (NASDAQ:XRAY) slips from a C to a D. Dentsply International designs and manufactures a range of dental products. To get an in-depth look at XRAY, get Portfolio Grader’s complete analysis of XRAY stock.
ArthroCare‘s (NASDAQ:ARTC) rating weakens this week, dropping to a D versus last week’s C. ArthroCare is a multi-business medical device Company that develops, manufactures and markets minimally invasive surgical products, many of which are based on its patented Coblation(r) technology. The stock also gets an F in Margin Growth. For more information, get Portfolio Grader’s complete analysis of ARTC stock.
Masimo Corp. (NASDAQ:MASI) earns a D this week, falling from last week’s grade of C. Masimo designs, develops and licenses medical signal processing and sensor technology for the noninvasive monitoring of physiological parameters. Investors seem to agree with the downgrade and have pushed down the share price 11.5% over the past month. For a full analysis of MASI stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
